De Lisle Partners LLP Uro Gen Pharma Ltd. Transaction History
De Lisle Partners LLP
- $433 Billion
- Q1 2024
A detailed history of De Lisle Partners LLP transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, De Lisle Partners LLP holds 77,093 shares of URGN stock, worth $1.22 Million. This represents 0.27% of its overall portfolio holdings.
Number of Shares
77,093Holding current value
$1.22 Million% of portfolio
0.27%Shares
1 transactions
Others Institutions Holding URGN
# of Institutions
113Shares Held
24MCall Options Held
46.9KPut Options Held
44.3K-
Rtw Investments, LP New York, NY3.26MShares$51.7 Million0.78% of portfolio
-
Great Point Partners LLC Greenwich, CT2.62MShares$41.6 Million9.62% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$36.6 Million0.26% of portfolio
-
Black Rock Inc. New York, NY1.72MShares$27.3 Million0.0% of portfolio
-
Cowen And Company, LLC1.63MShares$25.8 Million0.82% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $361M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...